Clinical Scientist Associate Director Joins Late-Stage Obesity Development Team in the UK

Amgen Expands Obesity Research Leadership with New Clinical Scientist Role in the UK

Amgen, the American multinational biopharmaceutical company headquartered in Thousand Oaks, California, has announced the creation of a new leadership position focused on advancing its late-stage obesity research. The company has appointed a Clinical Scientist Associate Director for Late Development Obesity, based in the United Kingdom, as part of its expanding efforts to develop innovative treatments for obesity and related conditions.

A Strategic Move in Obesity Drug Development

The appointment reflects Amgen’s growing commitment to obesity research, a field where the company has been rapidly accelerating its clinical trials. In June 2025, Amgen launched its Phase 3 MARITIME program, evaluating MariTide (maridebart cafraglutide), an investigational antibody-peptide conjugate designed to block the glucose-dependent insulinotropic polypeptide (GIP) receptor—a hormone pathway linked to insulin signaling and fat storage. The MARITIME program includes multiple studies, such as MARITIME-1 for individuals with overweight or obesity and MARITIME-2 for those with type 2 diabetes and obesity. Additional Phase 3 trials are exploring MariTide’s potential in cardiovascular disease, heart failure, kidney disease and obstructive sleep apnea.

With obesity affecting approximately one billion people worldwide, Amgen’s focus on this area aligns with its broader mission to tackle some of the world’s most pressing health challenges. The company’s 2025 financial report highlights obesity as a priority, alongside its established treatments for cardiovascular disease, osteoporosis, and autoimmune disorders.

Amgen’s UK Expansion and Global Manufacturing Investments

The new role in the UK underscores Amgen’s strategic investments in Europe, particularly in research and development. Earlier this year, Amgen announced an additional $300 million in U.S. Manufacturing investments, bringing its total investment to nearly $2 billion over the past year. While the UK-specific investment details were not disclosed in the discovery source, the appointment suggests a broader expansion of Amgen’s clinical research capabilities in Europe, a region with significant expertise in biopharmaceutical innovation.

Amgen’s CEO, Robert A. Bradway, has emphasized the company’s dedication to leveraging cutting-edge science to address unmet medical needs. The creation of this new position aligns with Amgen’s AI-enabled clinical development approach, which aims to streamline drug discovery and accelerate patient access to life-changing therapies.

The Broader Context: Obesity as a Global Health Priority

Obesity is a complex, multifactorial disease with far-reaching health consequences, including increased risks of type 2 diabetes, cardiovascular disease, and certain cancers. The World Health Organization (WHO) estimates that over 650 million adults worldwide were obese in 2016, a figure that has likely risen since. With limited long-term weight management solutions currently available, pharmaceutical interventions like MariTide represent a critical area of focus for companies like Amgen.

The UK, as a hub for clinical research, offers a strategic location for Amgen to conduct late-stage trials and collaborate with local healthcare providers. The appointment of a dedicated Clinical Scientist Associate Director for obesity research signals Amgen’s intent to deepen its engagement with European regulators, healthcare systems, and patient communities.

What Comes Next?

While the exact responsibilities of the new role have not been detailed in the discovery source, the appointment is likely to support Amgen’s ongoing MARITIME program and other obesity-related initiatives. The company’s Phase 3 trials are expected to provide critical data on MariTide’s safety and efficacy, potentially positioning it as a new treatment option for obesity and associated conditions.

Amgen’s expansion into obesity research also reflects broader industry trends, with multiple pharmaceutical companies investing in weight management solutions. As clinical trials progress, the company will need to navigate regulatory pathways, patient enrollment challenges, and market competition. The UK’s role in this process will be pivotal, given its established clinical trial infrastructure and proximity to key European markets.

This article is based on verified reporting and Amgen’s official statements. For further updates on the MARITIME program and obesity research, readers are encouraged to follow Amgen’s official communications and clinical trial registries.